Online inquiry

IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11009MR)

This product GTTS-WQ11009MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&CLEC12A gene. The antibody can be applied in Acute myeloid leukemia (AML) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_001207010.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 160364
UniProt ID P07766; Q5QGZ9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&CLEC12A, MCLA-117(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11009MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13640MR IVTScrip™ mRNA-Anti-TNFSF4, R4930(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA R4930
GTTS-WQ8227MR IVTScrip™ mRNA-Anti-KDR, HLX-06(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HLX-06
GTTS-WQ11098MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ15912MR IVTScrip™ mRNA-Anti-IL1B, XOMA 052(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA XOMA 052
GTTS-WQ2244MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ALX-0171
GTTS-WQ4407MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ8262MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ12467MR IVTScrip™ mRNA-Anti-IL20, NN-8226(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA NN-8226
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW